Authors
Discussion
Loading...
Member takes
Implication
Clinical review outlines mutation profiles and management strategies across myeloproliferative neoplasms, highlighting the necessity of risk-stratified therapy and bone marrow morphology.
Key Points
- To review the diagnostic criteria, mutational landscape, prognostic determinants, and clinical management strategies for BCR-ABL1-negative myeloproliferative neoplasms.
- Synthesized evidence regarding driver mutations (JAK2, CALR, MPL) and bone marrow morphologic criteria according to World Health Organization guidelines.
- Evaluated survival outcomes, thrombotic risks, and therapeutic modalities including phlebotomy, cytoreductive therapies, JAK inhibitors, and stem cell transplantation.
- Driver mutation frequencies differed by disease: JAK2 occurred in approximately 95% of PV, 60% of ET, and 60% of PMF, whereas CALR occurred in 20% of ET and 25% of PMF.
- Median survival for patients younger than 60 years was approximately 33 years for ET, 24 years for PV, and 15 years for PMF, with thrombosis and leukemic transformation serving as major complications.
- Management requires aspirin and a hematocrit target <45% in PV, first-line hydroxyurea for high-risk PV and ET, and stem cell transplantation as the primary disease-modifying option for high-risk PMF.
Cite This Study
Tefferi et al. (2015) studied this question.